SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

NCT07442565 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

506

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SYS6010
DRUG: Docetaxel

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.